Skip to content

Cumberland Pharmaceuticals Inc.: 10-Q filed 2016-11-03

What Cumberland Pharmaceuticals Inc. reported in its quarterly report filed 2016-11-03 (fiscal Q3 2016): 38 published measures, 104 facts as tagged in accession 0001628280-16-020795.

This filing

Form
10-Q (quarterly report)
Filed
2016-11-03
Fiscal period
fiscal Q3 2016
Accession
0001628280-16-020795 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Cumberland Pharmaceuticals Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2016-09-3091,074,271USD
At 2015-12-3191,918,959USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2016-09-3016,651,656USD
At 2015-12-3115,099,176USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2016-09-3074,529,758USD
At 2015-12-3176,887,908USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2016-09-3035,546,244USD
At 2015-12-3138,203,059USD
At 2015-09-3038,316,291USD
At 2014-12-3139,866,037USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2016-07-01 to 2016-09-30106,166USD92
2016-01-01 to 2016-09-30-194,989USD274
2015-07-01 to 2015-09-30126,613USD92
2015-01-01 to 2015-09-30580,292USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2016-01-01 to 2016-09-30-250,316USD274
2015-01-01 to 2015-09-304,553,496USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2016-01-01 to 2016-09-3098,275USD274
2015-01-01 to 2015-09-3096,768USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2016-01-01 to 2016-09-30-786,665USD274
2015-01-01 to 2015-09-30-4,096,906USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2016-01-01 to 2016-09-30-1,619,834USD274
2015-01-01 to 2015-09-30-2,006,336USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2016-09-3019,354,625USD
At 2015-12-3119,549,614USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2016-07-01 to 2016-09-3016,217,442shares92
2016-01-01 to 2016-09-3016,268,579shares274
2015-07-01 to 2015-09-3016,604,682shares92
2015-01-01 to 2015-09-3016,811,360shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2016-07-01 to 2016-09-3016,504,568shares92
2016-01-01 to 2016-09-3016,268,579shares274
2015-07-01 to 2015-09-3016,996,376shares92
2015-01-01 to 2015-09-3017,193,854shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2016-07-01 to 2016-09-300.01USD/shares92
2016-01-01 to 2016-09-30-0.01USD/shares274
2015-07-01 to 2015-09-300.01USD/shares92
2015-01-01 to 2015-09-300.03USD/shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2016-07-01 to 2016-09-300.01USD/shares92
2016-01-01 to 2016-09-30-0.01USD/shares274
2015-07-01 to 2015-09-300.01USD/shares92
2015-01-01 to 2015-09-300.03USD/shares273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2016-07-01 to 2016-09-3057,192USD92
2016-01-01 to 2016-09-30-159,282USD274
2015-07-01 to 2015-09-30193,439USD92
2015-01-01 to 2015-09-30530,885USD273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2016-09-30482,591USD
At 2015-12-31536,450USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2016-01-01 to 2016-09-30623,504USD274
2015-01-01 to 2015-09-30426,651USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2016-07-01 to 2016-09-30130,132USD92
2016-01-01 to 2016-09-30-475,760USD274
2015-07-01 to 2015-09-30270,884USD92
2015-01-01 to 2015-09-30948,931USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2016-09-3066,962,992USD
At 2015-12-3167,112,074USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2016-07-01 to 2016-09-3029,088USD92
2016-01-01 to 2016-09-3077,777USD274
2015-07-01 to 2015-09-3019,815USD92
2015-01-01 to 2015-09-3053,854USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2016-09-3011,685,931USD
At 2015-12-3112,411,747USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2016-09-306,658,196USD
At 2015-12-312,877,479USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2016-09-3021,172,570USD
At 2015-12-3121,168,596USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2016-09-306,672,300USD
At 2015-12-316,077,120USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2016-01-01 to 2016-09-301,879,395USD274
2015-01-01 to 2015-09-304,669,873USD273

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2016-09-304,983,227USD
At 2015-12-314,270,143USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2016-07-01 to 2016-09-30644,662USD92
2016-01-01 to 2016-09-302,029,914USD274
2015-07-01 to 2015-09-30757,442USD92
2015-01-01 to 2015-09-303,444,524USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2016-09-3016,195,631shares
At 2015-12-3116,379,501shares

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2016-09-3074,422,615USD
At 2015-12-3176,819,783USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2016-09-302,456,118USD
At 2015-12-313,101,839USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2016-07-01 to 2016-09-3095,488USD92
2016-01-01 to 2016-09-30-234,007USD274
2015-07-01 to 2015-09-30121,702USD92
2015-01-01 to 2015-09-30542,512USD273

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2016-07-01 to 2016-09-3095,488USD92
2016-01-01 to 2016-09-30-234,007USD274
2015-07-01 to 2015-09-30121,702USD92
2015-01-01 to 2015-09-30542,512USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2016-07-01 to 2016-09-301,865,575USD92
2016-01-01 to 2016-09-305,817,943USD274
2015-07-01 to 2015-09-301,794,279USD92
2015-01-01 to 2015-09-305,591,982USD273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2016-01-01 to 2016-09-301,785,057USD274
2015-01-01 to 2015-09-301,677,906USD273

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2016-07-01 to 2016-09-30562,722USD92
2016-01-01 to 2016-09-301,632,920USD274
2015-07-01 to 2015-09-30473,439USD92
2015-01-01 to 2015-09-301,471,879USD273

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2016-01-01 to 2016-09-30662,689USD274
2015-01-01 to 2015-09-3043,991USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-09-30595,180USD274
2015-01-01 to 2015-09-30293,665USD273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-09-30713,084USD274
2015-01-01 to 2015-09-30-1,394,280USD273

Inspect the source

Entity
Cumberland Pharmaceuticals Inc. / CIK 0001087294
Captured
2026-09-20T05:21:29.619Z
SEC response SHA-256
b37ed2fef35db1cde0c40b2233eb97cf370fc96d41a5c7d61b6a5a76a296e4a0

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001087294.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))